Increased PD-L1 expression has been observed on NSCLC cells with activating gene alterations in KRAS, EGFR, and ALK, which has been associated with upregulated MAPK, PI3K–AKT–mTOR signaling, and JAK–STAT3 activation [27,28,29,30,31,32,33]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.